Share on StockTwits
 

Equities researchers at Wedbush raised their price target on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $72.00 to $449.00 in a research report issued on Wednesday, Analyst Ratings Network reports. The firm currently has a “fair value” rating on the stock. Wedbush’s target price suggests a potential upside of 37.68% from the company’s current price.

In other Intercept Pharmaceuticals news, Director Srinivas Akkaraju sold 3,250 shares of Intercept Pharmaceuticals stock on the open market in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $267.94, for a total transaction of $870,805.00. Following the transaction, the director now directly owns 1,943 shares in the company, valued at approximately $520,607. The sale was disclosed in a document filed with the SEC, which is available at this link.

ICPT has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note to investors on Monday, January 13th. Separately, analysts at Citigroup Inc. raised their price target on shares of Intercept Pharmaceuticals to $600.00 in a research note to investors on Monday, January 13th. Finally, analysts at Janney Montgomery Scott raised their price target on shares of Intercept Pharmaceuticals to $300.00 in a research note to investors on Friday, January 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $483.50.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 5.64% on Wednesday, hitting $344.50. 800,864 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 52-week low of $30.38 and a 52-week high of $497.00. The stock has a 50-day moving average of $123.9 and a 200-day moving average of $69.70. The company’s market cap is $6.661 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $1.14. During the same quarter in the prior year, the company posted ($1.86) earnings per share. On average, analysts predict that Intercept Pharmaceuticals will post $-3.77 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.